Literature DB >> 24982390

Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient--a case report.

Iwona Homa1, Marek Sawicki2, Kamila Wojas-Krawczyk3, Marcin Nicoś4, Radosław Mlak5, Tomasz Powrózek3, Paweł Krawczyk3, Piotr Przybylski6, Elżbieta Czekajska-Chehab6, Janusz Milanowski7.   

Abstract

Anaplastic lymphoma kinase (ALK) gene re-arrangements are present in approximately 4% of patients with non-small cell lung cancer (NSCLC), mostly in non-smokers with adenocarcinoma. V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are more common in smokers. These molecular lesions were usually described as are mutually exclusive. We herein describe a rare case of co-existence of ALK and KRAS abnormalities in adenocarcinoma tumor with massive local growth (disproportionality of clinical symptoms) and rapid central nervous system (CNS) metastases spread. T3N1M0 stage tumor (size: 10×12×13 cm) in upper lobe of the right lung was diagnosed in a 56-year-old Caucasian male smoker. Adenocarcinoma of solid predominant was surgically resected with chest wall reconstruction. One month after surgery, CNS metastases were diagnosed and subsequently treated with radiotherapy. We noted an 8-month overall survival from tumor resection. In the case of comorbidity of disorders in the ALK (uncertain prognostic significance) and KRAS gene (described as unfavorable prognostic factor), these abnormalities may ultimately decide the course of the disease in the form of brain metastases. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  ALK rearrangement; CNS metastases; KRAS mutation; lung adenocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 24982390

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib.

Authors:  You-Cai Zhu; Bing Wan; Li-Xin Wu; Xing-Liang Li; Wen-Xian Wang; Chun-Wei Xu; Wu Zhuang; Jian-Guo Wei; Kai-Qi Du
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.